SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory Board (SAB) to include three additional key opinion leaders: James Krueger, M.D., Ph.D., from The Rockefeller University; Iain McInnes, C.B.E., Ph.D., F.R.C.P., F.R.S.E., F.Med.Sci., from the University of Glasgow; and John O’Shea, M.D., from the National

As with the younger study participants, no safety concerns or dose limiting toxicities were observed in older adults and pharmacodynamic analysis continued to demonstrate evidence of target engagement together with a biologic effect SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced additional results from the older adult follow-on cohorts from its completed Phase 1 trial

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety pro growing performance benefits Primary safety endpoint met and encouraging secondary performance objectives at 6 months (in 94 patients) and 12 months (in 25 patients) REGENERA™ achieved high levels of patient and surgeon satisfaction Patients to be followed for up to five years to assess long-term safety First regulatory approvals in the EU expected in early 2027 Tensive in San Francisco during the JP

Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd (“Engitix”), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, Switzerland, January 8, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces it has signed an exclusive licensing agreement with Nxera Pharma UK Ltd. (“Nxera”) for the development, manufacturing and commercialization of AGAMREE® (vamorolone) for the trea

HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal trial strategy for leptomeningeal metastases (LM). The meeting resulted in constructive discussion

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439.0

Leuven , Belgium. January 8, 2026 . Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. H

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for Sonelokimab (SLK) in Hidradenitis Suppurativa (HS) FDA feedback confirms that the Company may establish substantial evidence of effectiveness (SEE), without additional clinical trials in HS, with a BLA consisting of data from its existing VELA-1, VELA-2 and MIRA trials The FDA specif

Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal Degeneration Fund, and supported by existing investors Funds will advance laru-zova toward commercialization for treatment of X-linked retinitis pigmentosa and accelerate development of additional pipeline candidates LONDON and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage